PMID: 12870371Jul 23, 2003Paper

Impact of side-effects of atypical antipsychotics on non-compliance, relapse and cost

The Journal of International Medical Research
A MortimerD Meddis


Atypical antipsychotics generally have milder side-effects than conventional antipsychotics, but also differ among themselves in this respect. This study aimed to compare the impact of different side-effect profiles of individual atypical antipsychotics on non-compliance, relapse and cost in schizophrenia. A state-transition model was built using literature data supplemented by expert opinion. The model found that quetiapine and ziprasidone were similar in estimated non-compliance and relapse rates. Olanzapine and risperidone had higher estimated non-compliance and relapse rates, and incremental, 1-year, per-patient direct costs, using US-based cost data, of approximately $530 (95% confidence interval [CI] approximately $275, $800), and approximately $485 (95% CI approximately $235, $800), respectively, compared with quetiapine. Incremental costs attributable to different side-effect profiles were highly significant. This study shows that differing side-effect profiles of the newer antipsychotic agents are likely to lead to different compliance rates, and consequent variation in relapse rates. The cost implications of these heterogenous clinical outcomes are substantial.


Jan 1, 1995·Schizophrenia Bulletin·P J Weiden, M Olfson
Mar 1, 1995·Archives of General Psychiatry·R J Baldessarini, A C Viguera
Jan 1, 1994·Acta Psychiatrica Scandinavica. Supplementum·W W FleischhackerM Kurz
Jan 1, 1997·Archives of General Psychiatry·A C VigueraM Tohen
Aug 5, 1998·International Clinical Psychopharmacology·T R Barnes, M A McPhillips
Nov 26, 1998·The British Journal of Psychiatry : the Journal of Mental Science·P V TranC M Beasley
Feb 6, 1999·Journal of Clinical Psychopharmacology·D L KleinbergM Brecher
Sep 24, 1999·Acta Psychiatrica Scandinavica·O Kampman, K Lehtinen
Feb 26, 2000·The International Journal of Social Psychiatry·A G Awad, L N Voruganti
May 29, 2000·Psychological Medicine·S M Gilbody, F Song
Nov 7, 2000·PharmacoEconomics·E Lindström, K Bingefors
Jan 1, 2000·International Journal of Psychiatry in Clinical Practice·M BrecherA M Jones

❮ Previous
Next ❯


Aug 30, 2008·Neuropsychiatric Disease and Treatment·A Carlo Altamura, Jose M Goikolea
Jun 15, 2010·European Psychiatry : the Journal of the Association of European Psychiatrists·M De HertJ Peuskens
Apr 18, 2008·Journal of Behavior Therapy and Experimental Psychiatry·Hector W H TsangPatrick W Corrigan
Feb 1, 2005·Expert Review of Pharmacoeconomics & Outcomes Research·Reinhold Kilian, Thomas Becker
Dec 27, 2007·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·David R StruttonChristopher M Blanchette
Feb 20, 2004·Pharmacoepidemiology and Drug Safety
Jan 1, 2008·Applied Health Economics and Health Policy·Joep DamenMickael Lothgren
Aug 22, 2018·Journal of Market Access & Health Policy·Junwen ZhouMondher Toumi
Dec 2, 2008·Expert Opinion on Pharmacotherapy·Atheir Abbas, Bryan L Roth

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Progress in Neuro-psychopharmacology & Biological Psychiatry
Felipe Filardi da RochaAntônio Lúcio Teixeira
Primary Care Companion to the Journal of Clinical Psychiatry
Prakash S MasandAhmad Hameed
© 2021 Meta ULC. All rights reserved